Posted by Michael Wonder on 03 Feb 2026
Galderma announces US FDA acceptance of relabotulinumtoxinA biologics license application resubmission
2 February 2026 - Galderma today announced that the US FDA has accepted the BLA resubmission for relabotulinumtoxinA for the temporary improvement of moderate to severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults.
Galderma has worked closely with the US FDA to implement adjustments to its manufacturing process.
